Exploratory study of carboplatin plus the copper-lowering agent trientine in patients with advanced malignancies
详细信息 查看全文
- 作者：Siqing Fu (1)
Ming-Mo Hou (1) (4)
Jennifer Wheler (1)
David Hong (1)
Aung Naing (1)
Apostolia Tsimberidou (1)
Filip Janku (1)
Ralph Zinner (1)
Sarina Piha-Paul (1)
Gerald Falchook (1)
Macus Tien Kuo (2)
Razelle Kurzrock (3) - 关键词：Trientine ; Carboplatin ; Platinum resistance ; Copper ; Ceruloplasmin
- 刊名：Investigational New Drugs
- 出版年：2014
- 出版时间：June 2014
- 年：2014
- 卷：32
- 期：3
- 页码：465-472
- 全文大小：
- 参考文献：1. Wang D, Lippard SJ (2005) Cellular processing of platinum anticancer drugs. Nature reviews Drug discovery 4(4):307鈥?20. doi:10.1038/nrd1691 CrossRef
2. Kelland L (2007) The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 7(8):573鈥?84. doi:10.1038/nrc2167 CrossRef
3. Shahzad MM, Lopez-Berestein G, Sood AK (2009) Novel strategies for reversing platinum resistance. Drug Resist Updat 12(6):148鈥?52. doi:10.1016/j.drup.2009.09.001 CrossRef
4. Matsuo K, Lin YG, Roman LD, Sood AK (2010) Overcoming platinum resistance in ovarian carcinoma. Expert opinion on investigational drugs 19(11):1339鈥?354. doi:10.1517/13543784.2010.515585 CrossRef
5. Fu S, Hu W, Iyer R, Kavanagh JJ, Coleman RL, Levenback CF, Sood AK, Wolf JK, Gershenson DM, Markman M, Hennessy BT, Kurzrock R, Bast RC Jr (2011) Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer. Cancer 117(8):1661鈥?669. doi:10.1002/cncr.25701 CrossRef
6. Ishida S, Lee J, Thiele DJ, Herskowitz I (2002) Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proceedings of the National Academy of Sciences of the United States of America 99(22):14298鈥?4302. doi:10.1073/pnas.162491399 CrossRef
7. Song IS, Savaraj N, Siddik ZH, Liu P, Wei Y, Wu CJ, Kuo MT (2004) Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells. Molecular cancer therapeutics 3(12):1543鈥?549
8. Liang ZD, Stockton D, Savaraj N, Tien Kuo M (2009) Mechanistic comparison of human high-affinity copper transporter 1-mediated transport between copper ion and cisplatin. Molecular pharmacology 76(4):843鈥?53. doi:10.1124/mol.109.056416 CrossRef
9. Sinani D, Adle DJ, Kim H, Lee J (2007) Distinct mechanisms for Ctr1-mediated copper and cisplatin transport. J Biol Chem 282(37):26775鈥?6785. doi:10.1074/jbc.M703973200 CrossRef
10. Ishida S, McCormick F, Smith-McCune K, Hanahan D (2010) Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator. Cancer cell 17(6):574鈥?83. doi:10.1016/j.ccr.2010.04.011 CrossRef
11. Liang ZD, Long Y, Tsai WB, Fu S, Kurzrock R, Gagea-Iurascu M, Zhang F, Chen HH, Hennessy BT, Mills GB, Savaraj N, Kuo MT (2012) Mechanistic basis for overcoming platinum resistance using copper chelating agents. Mol Cancer Ther 11(11):2483鈥?494. doi:10.1158/1535-7163.MCT-12-0580 CrossRef
12. Chen HH, Yan JJ, Chen WC, Kuo MT, Lai YH, Lai WW, Liu HS, Su WC (2012) Predictive and prognostic value of human copper transporter 1 (hCtr1) in patients with stage III non-small-cell lung cancer receiving first-line platinum-based doublet chemotherapy. Lung Cancer 75(2):228鈥?34. doi:10.1016/j.lungcan.2011.06.011 CrossRef
13. Kim BE, Nevitt T, Thiele DJ (2008) Mechanisms for copper acquisition, distribution and regulation. Nat Chem Biol 4(3) (3):176鈥?85. doi: 10.1038/nchembio.72
14. Howell SB, Safaei R, Larson CA, Sailor MJ (2010) Copper transporters and the cellular pharmacology of the platinum-containing cancer drugs. Molecular pharmacology 77(6):887鈥?94. doi:10.1124/mol.109.063172 CrossRef
15. Liang ZD, Tsai WB, Lee MY, Savaraj N, Kuo MT (2012) Specificity protein 1 (sp1) oscillation is involved in copper homeostasis maintenance by regulating human high-affinity copper transporter 1 expression. Mol Pharmacol 81(3):455鈥?64. doi:10.1124/mol.111.076422 CrossRef
16. Kuo MT, Chen HH, Song IS, Savaraj N, Ishikawa T (2007) The roles of copper transporters in cisplatin resistance. Cancer metastasis reviews 26(1):71鈥?3. doi:10.1007/s10555-007-9045-3 CrossRef
17. Lu J (2010) Triethylenetetramine pharmacology and its clinical applications. Molecular cancer therapeutics 9(9):2458鈥?467. doi:10.1158/1535-7163.MCT-10-0523 CrossRef
18. Kuo MT, Fu S, Savaraj N, Chen HH (2012) Role of the human high-affinity copper transporter in copper homeostasis regulation and cisplatin sensitivity in cancer chemotherapy. Cancer Res 72(18):4616鈥?621. doi:10.1158/0008-5472.CAN-12-0888 CrossRef
19. ClinicalTrials.gov Available at: http://clinicaltrials.gov/ct2/show/NCT01178112. Accessed March 24, 2012
20. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5(6):649鈥?55 CrossRef
21. Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, Chen LL, Podoloff DA, Benjamin RS (2007) Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 25(13):1753鈥?759. doi:10.1200/JCO.2006.07.3049 CrossRef
22. Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Available at: http://www.acrin.org/Portals/0/Administration/Regulatory/CTCAE_4.02_2009-09-15_QuickReference_5x7.pdf. Accessed August 8, 2013
23. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). European journal of cancer 45(2):228鈥?47. doi:10.1016/j.ejca.2008.10.026 CrossRef
24. Chan A, Wong F, Arumanayagam M (1993) Serum ultrafiltrable copper, total copper and caeruloplasmin concentrations in gynaecological carcinomas. Annals of clinical biochemistry 30(Pt 6):545鈥?49 CrossRef
25. Muggia F (2009) Platinum compounds 30聽years after the introduction of cisplatin: implications for the treatment of ovarian cancer. Gynecol Oncol 112(1):275鈥?81. doi:10.1016/j.ygyno.2008.09.034 CrossRef
26. Shen DW, Pouliot LM, Hall MD, Gottesman MM (2012) Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. Pharmacol Rev 64(3):706鈥?21. doi:10.1124/pr.111.005637 CrossRef
27. Siddik ZH (2003) Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22(47):7265鈥?279. doi:10.1038/sj.onc.1206933 CrossRef
28. Fu S, Naing A, Fu C, Kuo MT, Kurzrock R (2012) Overcoming platinum resistance through the use of a copper-lowering agent. Mol Cancer Ther 11(6):1221鈥?225. doi:10.1158/1535-7163.MCT-11-0864 CrossRef
29. Chen HH, Song IS, Hossain A, Choi MK, Yamane Y, Liang ZD, Lu J, Wu LY, Siddik ZH, Klomp LW, Savaraj N, Kuo MT (2008) Elevated glutathione levels confer cellular sensitization to cisplatin toxicity by up-regulation of copper transporter hCtr1. Molecular pharmacology 74(3):697鈥?04. doi:10.1124/mol.108.047969 CrossRef
30. Hayashi M, Nishiya H, Chiba T, Endoh D, Kon Y, Okui T (2007) Trientine, a copper-chelating agent, induced apoptosis in murine fibrosarcoma cells in vivo and in vitro. J Vet Med Sci 69(2):137鈥?42 CrossRef
31. Yoshiji H, Yoshii J, Kuriyama S, Ikenaka Y, Noguchi R, Yanase K, Namisaki T, Kitade M, Yamazaki M, Fukui H (2005) Combination of copper-chelating agent, trientine, and methotrexate attenuates colorectal carcinoma development and angiogenesis in mice. Oncol Rep 14(1):213鈥?18
32. Yoshii J, Yoshiji H, Kuriyama S, Ikenaka Y, Noguchi R, Okuda H, Tsujinoue H, Nakatani T, Kishida H, Nakae D, Gomez DE, De Lorenzo MS, Tejera AM, Fukui H (2001) The copper-chelating agent, trientine, suppresses tumor development and angiogenesis in the murine hepatocellular carcinoma cells. Int J Cancer 94(6):768鈥?73. doi:10.1002/ijc.1537 CrossRef
33. Kavanagh J, Tresukosol D, Edwards C, Freedman R, Gonzalez de Leon C, Fishman A, Mante R, Hord M, Kudelka A (1995) Carboplatin reinduction after taxane in patients with platinum-refractory epithelial ovarian cancer. J Clin Oncol 13(7):1584鈥?588
34. Leitao MM Jr, Hummer A, Dizon DS, Aghajanian C, Hensley M, Sabbatini P, Venkatraman E, Spriggs DR (2003) Platinum retreatment of platinum-resistant ovarian cancer after nonplatinum therapy. Gynecol Oncol 91(1):123鈥?29 CrossRef
35. Gartner EM, Griffith KA, Pan Q, Brewer GJ, Henja GF, Merajver SD, Zalupski MM (2009) A pilot trial of the anti-angiogenic copper lowering agent tetrathiomolybdate in combination with irinotecan, 5-flurouracil, and leucovorin for metastatic colorectal cancer. Investigational new drugs 27(2):159鈥?65. doi:10.1007/s10637-008-9165-9 CrossRef
36. Brewer GJ, Askari F, Dick RB, Sitterly J, Fink JK, Carlson M, Kluin KJ, Lorincz MT (2009) Treatment of Wilson鈥檚 disease with tetrathiomolybdate: V. Control of free copper by tetrathiomolybdate and a comparison with trientine. Transl Res 154(2):70鈥?7. doi:10.1016/j.trsl.2009.05.002 CrossRef - 作者单位：Siqing Fu (1)
Ming-Mo Hou (1) (4)
Jennifer Wheler (1)
David Hong (1)
Aung Naing (1)
Apostolia Tsimberidou (1)
Filip Janku (1)
Ralph Zinner (1)
Sarina Piha-Paul (1)
Gerald Falchook (1)
Macus Tien Kuo (2)
Razelle Kurzrock (3)
1. Department of Investigational Cancer Therapeutics, Unit 0455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA
4. Division of Hematology-Oncology, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan
2. Department of Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
3. University of California San Diego, Moores Cancer Center, La Jolla, CA, USA - ISSN：1573-0646
文摘